(Q38395160)

English

Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma

scientific article published on 06 March 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 September 2017

Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma (English)

1 reference

Europe PubMed Central

2 September 2017

2

object named as

Martha Q Lacy

1 reference

Europe PubMed Central

2 September 2017

Charles A. Dinarello

6

object named as

Charles A Dinarello

1 reference

Europe PubMed Central

2 September 2017

Steven R Zeldenrust

3

object named as

Steven R Zeldenrust

1 reference

Europe PubMed Central

2 September 2017

1

object named as

John A Lust

1 reference

Europe PubMed Central

2 September 2017

author name string

Thomas E Witzig

4

1 reference

Europe PubMed Central

2 September 2017

Laurie L Moon-Tasson

5

1 reference

Europe PubMed Central

2 September 2017

Kathleen A Donovan

7

1 reference

Europe PubMed Central

2 September 2017

publication date

6 March 2016

1 reference

Europe PubMed Central

2 September 2017

American Journal of Hematology

1 reference

Europe PubMed Central

2 September 2017

91

1 reference

Europe PubMed Central

2 September 2017

6

1 reference

Europe PubMed Central

2 September 2017

571-574

1 reference

Europe PubMed Central

2 September 2017

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24352

21 January 2018

Myeloma today: Disease definitions and treatment advances

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24352

21 January 2018

Smoldering, asymptomatic stage 1, and indolent myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24352

21 January 2018

Smoldering multiple myeloma requiring treatment: time for a new definition?

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24352

21 January 2018

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24352

21 January 2018

Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24352

21 January 2018

Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24352

21 January 2018

Why not treat human cancer with interleukin-1 blockade?

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24352

21 January 2018

Targeting the pathogenic role of interleukin 1{beta} in the progression of smoldering/indolent myeloma to active disease

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24352

21 January 2018

Induction of chromosomal aberrations and growth-transformation of lymphoblastoid cell lines by inhibition of reactive oxygen species-induced apoptosis with interleukin-6.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24352

21 January 2018

Inflammation-induced cell proliferation potentiates DNA damage-induced mutations in vivo

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24352

21 January 2018

Multiple myeloma in World Trade Center responders: a case series

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24352

21 January 2018

Association between World Trade Center exposure and excess cancer risk

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24352

21 January 2018

Association of classical and related inflammatory markers with high-sensitivity C-reactive protein in healthy individuals: results from the Stanislas cohort

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24352

21 January 2018

Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24352

21 January 2018

Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

1 reference

https://api.crossref.org/works/10.1002%2FAJH.24352

21 January 2018

Identifiers

10.1002/AJH.24352

1 reference

Europe PubMed Central

2 September 2017

1 reference

Europe PubMed Central

2 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38395160&oldid=1757614548"